Overview
Clinical Strategies for Incorporating Immunotherapy in Advanced Breast Cancer
Insights for Surgeons and Oncologists
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Six expert faculty discuss advances in immunotherapy as it relates to breast cancer. This interview-style format is based on follow-up coverage from the “Immunotherapy and Breast Cancer” symposium at the Society of Surgical Oncology 2018 Annual Cancer Symposium, held on March 23, 2018 in Chicago, Illinois. PowerPoint slides from the symposium, as well as a written transcript of the interviews, are available for download.
This activity is intended for surgical oncologists, medical oncologists, and other healthcare providers involved in the care of patients with breast cancer.
Immuno-oncology is a significant departure from conventional treatment, resulting in rapid changes in oncology practice that continue to develop. Due to this new and rapidly changing aspect of cancer therapy, many surgeons are not up to date or do not have clinical competency with this developing field. The importance of understanding the immune microenvironment, how immunotherapy has been used in cancer treatment to date, and how immunotherapies can be incorporated into surgical oncology practice will be described in this activity, particularly in regards to the treatment of breast cancer.
Upon completion of this activity, participants will be able to:
• Describe how the tumor immune microenvironment may clinically impact patients with breast cancer
• Review current immunotherapy treatment options available and in development for patients with breast cancer
• Identify potential treatments that may be combined with immunotherapy to enhance treatment response
• Describe how the tumor immune microenvironment may clinically impact patients with breast cancer
• Review current immunotherapy treatment options available and in development for patients with breast cancer
• Identify potential treatments that may be combined with immunotherapy to enhance treatment response
This activity is sponsored by the Society of Surgical Oncology(SSO) and the Academy for Continued Healthcare Learning (ACHL).
This activity is supported by an educational grant from Merck & Company.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
2. Compatible with Windows PC and MAC (256 MB of RAM higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Barbara A. Pockaj, MD (Moderator)
Head of Oncologic Surgery
Mayo Clinic
Phoenix, Arizona
Head of Oncologic Surgery
Mayo Clinic
Phoenix, Arizona
Richard L. White, MD (Moderator)
Chief, Division of Surgical Oncology
Levine Cancer Institute, Atrium Health
Charlotte, North Carolina
Brian Czerniecki, MD, PhD
Chair, Department of Breast Oncology
Moffit Cancer Center
Tampa, Florida
Elizabeth A. Mittendorf, MD, PhD
Director, Breast Immuno-Oncology Program
Dana-Farber/Brigham and Women's Cancer Center
Boston, Massachusetts
Rita Nanda, MD
Co-Director, Breast Oncology Program
University of Chicago Medical Center
Chicago, Illinois
George Plitas, MD
Jeanne A. Petrek Junior Faculty Chair
Memorial Sloan Kettering Cancer Center
New York, New York
SSO requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
The following financial relationships have been provided:
Brian Czerniecki, MD, PhD
Consultant: ImmunoRestoration
Elizabeth A. Mittendorf, MD, PhD
Advisory Board: Amgen
Rita Nanda, MD
Advisory Board: AstraZeneca, Celgene, Genentech, Merck, Puma, Syndax
Research: Celgene, Corcept Therapeutics, Merck
Other: G1 Therapeutics (DSMB)
Other: G1 Therapeutics (DSMB)
George Plitas, MD
Advisory Board: Tizona Therapeutics, Merck
The following faculty have no financial relationships to disclose:
Barbara A. Pockaj, MD
Richard L. White, MD
Discussion of Off-Label, Investigational, or Experimental Drug Use: None
SSO, ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporters. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
Participants are required to complete the pre-test, view the online activity, and complete the post-test and evaluation. To receive credit, 80% or greater must be achieved on the post-test. There is no fee to participate in the activity or for the generation of the certificate.
SSO is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
SSO designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
SSO designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The SSO has approved this activity for up to 1 self-assessment credit that may be applied to the American Board of Surgery Continuous Certification Program.